Skip to main content
Premium Trial:

Request an Annual Quote

SQI, Algorithme Building Assay for Heparin Immunogenicity Testing

NEW YORK (GenomeWeb News) – SQI Diagnostics and Algorithme Pharma today said they are co-developing a proof-of-concept assay for immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

The assay is based on SQI's Ig Plex multiplexing technology and is expected to be available on all of the Toronto-based firm's fully automated analytical systems, including its SQIDlite and SQIDworks platforms.

The test will provide drug developers and contract research organizations quantitative results for all three isotopes of heparin-induced thrombocytopenia (HIT) antibodies in a single test, SQI and Algorithme said. Using SQI's automated platform will also improve the benefits of multiplexing and reduce the time and labor necessary to process and analyze blood samples during the drug development and immunogenicity testing, they added.

"Because HIT antibodies are potentially produced with all heparin-based biosimilars, Algorithme, with this proof of concept completed, will have a 'shelf-ready' multiplexed assay ready to implement and deliver very competitive HIT testing to the many pharmaceutical companies who are building heparin biosimilar compounds," Robert Masse, vice president of Large Molecule Bioanalysis of Aligorithme Pharma, said in a statement.

Based in Laval, Quebec, Algorithme provides early stage clinical development studies to pharmaceutical and biotechnology companies.